# A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

> **NCT04644770** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 144 (actual)

## Conditions studied

- Prostatic Neoplasms
- Adenocarcinoma

## Interventions

- **DRUG:** JNJ-69086420
- **DRUG:** JNJ-78278343
- **RADIATION:** Stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT04644770
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-12
- **Primary completion:** 2026-12-08
- **Final completion:** 2026-12-08
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644770, "A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04644770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*